We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
News

CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent

CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
News

CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CODA Genomics has announced that the US Patent and Trademark Office has issued US Patent 7,262,031 to its two founding scientists, University of California, Irvine (UCI) professors, Richard H. Lathrop and G. Wesley Hatfield.

The technology was developed under an Information Technology Research grant from the National Science Foundation jointly in the School of Medicine and the Donald Bren School of Information and Computer Sciences at UCI. The Company has licensed this patent exclusively from the UCI’s Office of Technology Assessment (OTA).

US Patent 7,262,031 entitled, “Method for Producing a Synthetic Gene or Other DNA Sequence,” teaches how to use a global (across all possible correct and incorrect gene assemblies) optimization method for the choice of DNA code to make a given protein. Properly chosen DNA enables the thermodynamically controlled self-assembly of only the desired DNA product(s). The synthetic gene is simultaneously optimized for many other parameters that affect the successful use of the gene to make protein efficiently in any desired biological system.

Robert J Molinari, Ph.D., CODA’s CEO said, “This broad protection of CODA’s breakthrough technology will allow the company to aggressively market its high-yielding Hot- Rod™ genes, and other optimized gene variant sets. For the customer, it allows a scaleable way to test a large number of gene and protein variants for desirable properties.”

Advertisement